{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:49:40Z","timestamp":1790470180265,"version":"4.1.0"},"reference-count":71,"publisher":"American Association for Cancer Research (AACR)","issue":"1","funder":[{"DOI":"10.13039\/100000002","name":"NIH NCI","doi-asserted-by":"publisher","award":["CA163800"],"award-info":[{"award-number":["CA163800"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"DOD","doi-asserted-by":"publisher","award":["W81XWH1910166"],"award-info":[{"award-number":["W81XWH1910166"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002576","name":"ACS","doi-asserted-by":"publisher","award":["IRG16-123-13"],"award-info":[{"award-number":["IRG16-123-13"]}],"id":[{"id":"10.13039\/100002576","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MSMT CZ","award":["LH15104"],"award-info":[{"award-number":["LH15104"]}]},{"DOI":"10.13039\/100009326","name":"CRS","doi-asserted-by":"publisher","award":["16255"],"award-info":[{"award-number":["16255"]}],"id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"NSFC","doi-asserted-by":"publisher","award":["81872924"],"award-info":[{"award-number":["81872924"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scholarship Council","award":["201807060002"],"award-info":[{"award-number":["201807060002"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,6,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Persistence of drug-resistant quiescent leukemic stem cells (LSC) and impaired natural killer (NK) cell immune response account for relapse of chronic myelogenous leukemia (CML). Inactivation of protein phosphatase 2A (PP2A) is essential for CML-quiescent LSC survival and NK cell antitumor activity. Here we show that MIR300 has antiproliferative and PP2A-activating functions that are dose dependently differentially induced by CCND2\/CDK6 and SET inhibition, respectively. MIR300 is upregulated in CML LSCs and NK cells by bone marrow microenvironment (BMM) signals to induce quiescence and impair immune response, respectively. Conversely, BCR-ABL1 downregulates MIR300 in CML progenitors to prevent growth arrest and PP2A-mediated apoptosis. Quiescent LSCs escape apoptosis by upregulating TUG1 long noncoding RNA that uncouples and limits MIR300 function to cytostasis. Genetic and pharmacologic MIR300 modulation and\/or PP2A-activating drug treatment restore NK cell activity, inhibit BMM-induced growth arrest, and selectively trigger LSC apoptosis in vitro and in patient-derived xenografts; hence, the importance of MIR300 and PP2A activity for CML development and therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Tumor-na\u00efve microenvironment\u2013induced MIR300 is the only tumor suppressor miRNA that induces CML LSC quiescence while inhibiting NK cell antitumor immune response, and CML LSC\/progenitor cell apoptosis through its anti-proliferative and PP2A-activating functions, respectively. Thus, the importance of MIR300 and PP2A-activating drugs for formation\/survival and eradication of drug-resistant CML LSCs, respectively.<\/jats:p>\n                    <jats:p>See related commentary by Broxmeyer, p. 13.<\/jats:p>\n                    <jats:p>This article is highlighted in the In This Issue feature, p. 5<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.bcd-19-0039","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T14:15:10Z","timestamp":1583331310000},"page":"48-67","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on\n                    <i>MIR300<\/i>\n                    Antiproliferative and PP2A-Activating Functions"],"prefix":"10.1158","volume":"1","author":[{"given":"Giovannino","family":"Silvestri","sequence":"first","affiliation":[{"name":"1Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland."},{"name":"2Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Trotta","sequence":"additional","affiliation":[{"name":"2Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland."},{"name":"3Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Stramucci","sequence":"additional","affiliation":[{"name":"1Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland."},{"name":"2Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin J.","family":"Ellis","sequence":"additional","affiliation":[{"name":"4Department of Molecular Virology Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio."},{"name":"5Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason G.","family":"Harb","sequence":"additional","affiliation":[{"name":"4Department of Molecular Virology Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio."},{"name":"5Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Neviani","sequence":"additional","affiliation":[{"name":"4Department of Molecular Virology Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio."},{"name":"5Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3869-2463","authenticated-orcid":false,"given":"Shuzhen","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Kathrin","family":"Eisfeld","sequence":"additional","affiliation":[{"name":"4Department of Molecular Virology Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio."},{"name":"5Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Walker","sequence":"additional","affiliation":[{"name":"4Department of Molecular Virology Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio."},{"name":"5Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[{"name":"6Division of Hematopoietic Stem Cell and Leukemia Research, City of Hope National Medical Center, Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara","family":"Srutova","sequence":"additional","affiliation":[{"name":"7Institute of Hematology and Blood Transfusion, University of Prague, Prague, Czech Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Gambacorti-Passerini","sequence":"additional","affiliation":[{"name":"8Hematology and Clinical Research Unit, San Gerardo Hospital, Monza, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Pineda","sequence":"additional","affiliation":[{"name":"9Department of Health Sciences, School of Health and Human Services, National University, San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona H. M.","family":"Jamieson","sequence":"additional","affiliation":[{"name":"10Department of Medicine and Moores Cancer Center, University of California, San Diego, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Stagno","sequence":"additional","affiliation":[{"name":"11Division of Hematology and Unit of Medical Oncology, A.O.U. \u201cPoliclinico-Vittorio Emanuele\u201d, University of Catania, Catania, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vigneri","sequence":"additional","affiliation":[{"name":"11Division of Hematology and Unit of Medical Oncology, A.O.U. \u201cPoliclinico-Vittorio Emanuele\u201d, University of Catania, Catania, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Nteliopoulos","sequence":"additional","affiliation":[{"name":"12Department of Haematology, Hammersmith Hospital, Imperial College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa C.","family":"May","sequence":"additional","affiliation":[{"name":"12Department of Haematology, Hammersmith Hospital, Imperial College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair G.","family":"Reid","sequence":"additional","affiliation":[{"name":"12Department of Haematology, Hammersmith Hospital, Imperial College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiro","family":"Garzon","sequence":"additional","affiliation":[{"name":"4Department of Molecular Virology Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio."},{"name":"5Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis-Claude","family":"Roy","sequence":"additional","affiliation":[{"name":"13Department of Hematology and Cellular Therapy Laboratory, H\u00f4pital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moutuaata M.","family":"Moutuou","sequence":"additional","affiliation":[{"name":"13Department of Hematology and Cellular Therapy Laboratory, H\u00f4pital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Guimond","sequence":"additional","affiliation":[{"name":"13Department of Hematology and Cellular Therapy Laboratory, H\u00f4pital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hokland","sequence":"additional","affiliation":[{"name":"14Department of Hematology, Aarhus University Hospital, Aarhus, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[{"name":"15Division of Hematology and Hematologic Malignancies and Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett","family":"Fitzgerald","sequence":"additional","affiliation":[{"name":"16Center for Advanced Fetal Care University, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Harman","sequence":"additional","affiliation":[{"name":"16Center for Advanced Fetal Care University, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Dazzi","sequence":"additional","affiliation":[{"name":"17Division of Cancer Studies, Rayne Institute, King's College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Milojkovic","sequence":"additional","affiliation":[{"name":"12Department of Haematology, Hammersmith Hospital, Imperial College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane F.","family":"Apperley","sequence":"additional","affiliation":[{"name":"12Department of Haematology, Hammersmith Hospital, Imperial College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[{"name":"6Division of Hematopoietic Stem Cell and Leukemia Research, City of Hope National Medical Center, Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfei","family":"Qi","sequence":"additional","affiliation":[{"name":"2Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina Machova","family":"Polakova","sequence":"additional","affiliation":[{"name":"7Institute of Hematology and Blood Transfusion, University of Prague, Prague, Czech Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zou","sequence":"additional","affiliation":[{"name":"2Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Fan","sequence":"additional","affiliation":[{"name":"2Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R.","family":"Baer","sequence":"additional","affiliation":[{"name":"1Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland."},{"name":"2Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Calabretta","sequence":"additional","affiliation":[{"name":"18Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Perrotti","sequence":"additional","affiliation":[{"name":"1Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland."},{"name":"2Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland."},{"name":"12Department of Haematology, Hammersmith Hospital, Imperial College London, London, United Kingdom."},{"name":"19Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"key":"2023122301070593200_bib1","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"key":"2023122301070593200_bib2","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology","volume":"16","author":"Radich","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"2023122301070593200_bib3","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"key":"2023122301070593200_bib4","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2008-05-158253","article-title":"Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib","volume":"113","author":"Yong","year":"2009","journal-title":"Blood"},{"key":"2023122301070593200_bib5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-3-319-97746-1_6","article-title":"Preservation of quiescent chronic myelogenous leukemia stem cells by the bone marrow microenvironment","volume":"1100","author":"Shah","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"2023122301070593200_bib6","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.3389\/fimmu.2019.02357","article-title":"Natural killer cells in myeloid malignancies: immune surveillance, NK cell dysfunction, and pharmacological opportunities to bolster the endogenous NK cells","volume":"10","author":"Carlsten","year":"2019","journal-title":"Front Immunol"},{"key":"2023122301070593200_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bbacli.2016.08.002","article-title":"The broken \u201cOff\u201d switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance","volume":"6","author":"Ruvolo","year":"2016","journal-title":"BBA Clin"},{"key":"2023122301070593200_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein","volume":"8","author":"Neviani","year":"2005","journal-title":"Cancer Cell"},{"key":"2023122301070593200_bib9","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Neviani","year":"2013","journal-title":"J Clin Invest"},{"key":"2023122301070593200_bib10","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1158\/1078-0432.CCR-13-2575","article-title":"Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia","volume":"20","author":"Agarwal","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2023122301070593200_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau0416","article-title":"Comment on \u201cPP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia\u201d","volume":"11","author":"Perrotti","year":"2019","journal-title":"Sci Transl Med"},{"key":"2023122301070593200_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan8735","article-title":"PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL(+) human leukemia","volume":"10","author":"Lai","year":"2018","journal-title":"Sci Transl Med"},{"key":"2023122301070593200_bib13","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3324\/haematol.2014.113852","article-title":"A hostel for the hostile: the bone marrow niche in hematologic neoplasms","volume":"100","author":"Krause","year":"2015","journal-title":"Haematologica"},{"key":"2023122301070593200_bib14","doi-asserted-by":"crossref","first-page":"4979474","DOI":"10.1155\/2017\/4979474","article-title":"The leukemic stem cell niche: adaptation to \u201cHypoxia\u201d versus oncogene addiction","volume":"2017","author":"Cheloni","year":"2017","journal-title":"Stem Cells Int"},{"key":"2023122301070593200_bib15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.molimm.2018.07.022","article-title":"MicroRNA regulation of natural killer cell development and function in leukemia","volume":"115","author":"Saultz","year":"2019","journal-title":"Mol Immunol"},{"key":"2023122301070593200_bib16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fonc.2015.00043","article-title":"The interplay between PP2A and microRNAs in leukemia","volume":"5","author":"Ruvolo","year":"2015","journal-title":"Front Oncol"},{"key":"2023122301070593200_bib17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40778-016-0057-1","article-title":"MicroRNAs in control of stem cells in normal and malignant hematopoiesis","volume":"2","author":"Roden","year":"2016","journal-title":"Curr Stem Cell Rep"},{"key":"2023122301070593200_bib18","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nm.4499","article-title":"Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia","volume":"24","author":"Zhang","year":"2018","journal-title":"Nat Med"},{"key":"2023122301070593200_bib19","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/jcb.26270","article-title":"MicroRNA-300 promotes apoptosis and inhibits proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt\/beta-catenin signaling pathway by targeting CUL4B in pancreatic cancer cells","volume":"119","author":"Zhang","year":"2018","journal-title":"J Cell Biochem"},{"key":"2023122301070593200_bib20","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/blood-2013-04-495374","article-title":"Preclinical and clinical efficacy of XPO1\/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias","volume":"122","author":"Walker","year":"2013","journal-title":"Blood"},{"key":"2023122301070593200_bib21","first-page":"535","article-title":"Critical role for cyclin D2 in BCR\/ABL-induced proliferation of hematopoietic cells","volume":"62","author":"Jena","year":"2002","journal-title":"Cancer Res"},{"key":"2023122301070593200_bib22","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.stem.2015.01.017","article-title":"CDK6 levels regulate quiescence exit in human hematopoietic stem cells","volume":"16","author":"Laurenti","year":"2015","journal-title":"Cell Stem Cell"},{"key":"2023122301070593200_bib23","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.stemcr.2017.10.009","article-title":"Small RNA sequencing reveals Dlk1-Dio3 locus-embedded MicroRNAs as major drivers of ground-state pluripotency","volume":"9","author":"Moradi","year":"2017","journal-title":"Stem Cell Reports"},{"key":"2023122301070593200_bib24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1634\/stemcells.20-4-347","article-title":"Hypoxia modifies proliferation and differentiation of CD34(+) CML cells","volume":"20","author":"Desplat","year":"2002","journal-title":"Stem Cells"},{"key":"2023122301070593200_bib25","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1182\/blood-2005-08-3181","article-title":"Inducible activation of CEBPB, a gene negatively regulated by BCR\/ABL, inhibits proliferation and promotes differentiation of BCR\/ABL-expressing cells","volume":"107","author":"Guerzoni","year":"2006","journal-title":"Blood"},{"key":"2023122301070593200_bib26","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/leu.2012.258","article-title":"C\/EBPbeta promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion","volume":"27","author":"Hayashi","year":"2013","journal-title":"Leukemia"},{"key":"2023122301070593200_bib27","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1182\/blood.V88.6.2279.bloodjournal8862279","article-title":"CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis","volume":"88","author":"Pierson","year":"1996","journal-title":"Blood"},{"key":"2023122301070593200_bib28","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"key":"2023122301070593200_bib29","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1097\/TP.0b013e3181a285b0","article-title":"The immunosuppressive properties of mesenchymal stem cells","volume":"87","author":"Siegel","year":"2009","journal-title":"Transplantation"},{"key":"2023122301070593200_bib30","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood-2010-05-285130","article-title":"The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells","volume":"117","author":"Trotta","year":"2011","journal-title":"Blood"},{"key":"2023122301070593200_bib31","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","article-title":"Immune effector recovery in chronic myeloid leukemia and treatment-free remission","volume":"8","author":"Hughes","year":"2017","journal-title":"Front Immunol"},{"key":"2023122301070593200_bib32","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia","volume":"94","author":"Holyoake","year":"1999","journal-title":"Blood"},{"key":"2023122301070593200_bib33","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.biopha.2017.01.150","article-title":"Long non-coding RNA TUG1 promotes cell proliferation and metastasis by negatively regulating miR-300 in gallbladder carcinoma","volume":"88","author":"Ma","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"2023122301070593200_bib34","doi-asserted-by":"crossref","first-page":"17100","DOI":"10.1002\/jcp.28464","article-title":"Taurine-upregulated gene 1: a functional long noncoding RNA in tumorigenesis","volume":"234","author":"Ghaforui-Fard","year":"2019","journal-title":"J Cell Physiol"},{"key":"2023122301070593200_bib35","first-page":"2377","article-title":"Long non-coding RNA TUG1 can promote proliferation and migration of pancreatic cancer via EMT pathway","volume":"21","author":"Qin","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2023122301070593200_bib36","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1182\/blood-2014-12-618090","article-title":"TGF-beta signaling in the control of hematopoietic stem cells","volume":"125","author":"Blank","year":"2015","journal-title":"Blood"},{"key":"2023122301070593200_bib37","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/ni.3204","article-title":"The transcription factor Foxm1 is essential for the quiescence and maintenance of hematopoietic stem cells","volume":"16","author":"Hou","year":"2015","journal-title":"Nat Immunol"},{"key":"2023122301070593200_bib38","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1111\/cas.13765","article-title":"Targeting the FOXM1-regulated long noncoding RNA TUG1 in osteosarcoma","volume":"109","author":"Li","year":"2018","journal-title":"Cancer Sci"},{"key":"2023122301070593200_bib39","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1002\/jcb.26052","article-title":"FOXM1 transcription factor: a new component of chronic myeloid leukemia stem cell proliferation advantage","volume":"118","author":"Mancini","year":"2017","journal-title":"J Cell Biochem"},{"key":"2023122301070593200_bib40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nature18288","article-title":"Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells","volume":"534","author":"Abraham","year":"2016","journal-title":"Nature"},{"key":"2023122301070593200_bib41","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"2023122301070593200_bib42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fonc.2015.00021","article-title":"From the biology of PP2A to the PADs for therapy of hematologic malignancies","volume":"5","author":"Ciccone","year":"2015","journal-title":"Front Oncol"},{"key":"2023122301070593200_bib43","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.4161\/rna.21998","article-title":"Dose-dependent differential mRNA target selection and regulation by let-7a-7f and miR-17-92 cluster microRNAs","volume":"9","author":"Shu","year":"2012","journal-title":"RNA Biol"},{"key":"2023122301070593200_bib44","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1182\/blood-2007-05-090472","article-title":"Identification of novel posttranscriptional targets of the BCR\/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR\/ABL leukemogenesis","volume":"111","author":"Eiring","year":"2008","journal-title":"Blood"},{"key":"2023122301070593200_bib45","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.bbrc.2015.10.055","article-title":"microRNA-26a and -584 inhibit the colorectal cancer progression through inhibition of the binding of hnRNP A1-CDK6 mRNA","volume":"467","author":"Konishi","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"2023122301070593200_bib46","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/S1470-2045(12)70558-2","article-title":"Protein phosphatase 2A: a target for anticancer therapy","volume":"14","author":"Perrotti","year":"2013","journal-title":"Lancet Oncol"},{"key":"2023122301070593200_bib47","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12957-016-0997-z","article-title":"Microarray data analysis to identify crucial genes regulated by CEBPB in human SNB19 glioma cells","volume":"14","author":"Du","year":"2016","journal-title":"World J Surg Oncol"},{"key":"2023122301070593200_bib48","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/hep.20333","article-title":"C\/EBP beta isoforms LIP and LAP modulate progression of the cell cycle in the regenerating mouse liver","volume":"40","author":"Luedde","year":"2004","journal-title":"Hepatology"},{"key":"2023122301070593200_bib49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.stem.2016.05.004","article-title":"ADAR1 activation drives leukemia stem cell self-renewal by impairing let-7 biogenesis","volume":"19","author":"Zipeto","year":"2016","journal-title":"Cell Stem Cell"},{"key":"2023122301070593200_bib50","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2017-05-783845","article-title":"hsa-mir183\/EGR1-mediated regulation of E2F1 is required for CML stem\/progenitor cell survival","volume":"131","author":"Pellicano","year":"2018","journal-title":"Blood"},{"key":"2023122301070593200_bib51","doi-asserted-by":"crossref","first-page":"e27639","DOI":"10.1371\/journal.pone.0027639","article-title":"Natural killer cell mediated missing-self recognition can protect mice from primary chronic myeloid leukemia in vivo","volume":"6","author":"Kijima","year":"2011","journal-title":"PLoS One"},{"key":"2023122301070593200_bib52","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3389\/fimmu.2013.00490","article-title":"The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity","volume":"4","author":"Baginska","year":"2013","journal-title":"Front Immunol"},{"key":"2023122301070593200_bib53","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3389\/fimmu.2015.00482","article-title":"Critical role of tumor microenvironment in shaping NK cell functions: implication of hypoxic stress","volume":"6","author":"Hasmim","year":"2015","journal-title":"Front Immunol"},{"key":"2023122301070593200_bib54","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.stem.2015.02.014","article-title":"Normal and leukemic stem cell niches: insights and therapeutic opportunities","volume":"16","author":"Schepers","year":"2015","journal-title":"Cell Stem Cell"},{"key":"2023122301070593200_bib55","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2012-12-467597","article-title":"Overexpression of miR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells","volume":"121","author":"Trotta","year":"2013","journal-title":"Blood"},{"key":"2023122301070593200_bib56","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2009-05-220814","article-title":"Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice","volume":"114","author":"Costinean","year":"2009","journal-title":"Blood"},{"key":"2023122301070593200_bib57","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1159\/000479990","article-title":"The Lncrna-TUG1\/EZH2 axis promotes pancreatic cancer cell proliferation, migration and EMT phenotype formation through sponging Mir-382","volume":"42","author":"Zhao","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"2023122301070593200_bib58","doi-asserted-by":"crossref","first-page":"13616","DOI":"10.1038\/ncomms13616","article-title":"Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment","volume":"7","author":"Katsushima","year":"2016","journal-title":"Nat Commun"},{"key":"2023122301070593200_bib59","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/leu.2011.325","article-title":"Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors","volume":"26","author":"Traer","year":"2012","journal-title":"Leukemia"},{"key":"2023122301070593200_bib60","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fimmu.2016.00091","article-title":"Natural killer cells for immunotherapy - advantages of the NK-92 cell line over blood NK cells","volume":"7","author":"Klingemann","year":"2016","journal-title":"Front Immunol"},{"key":"2023122301070593200_bib61","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","article-title":"Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche","volume":"13","author":"Schepers","year":"2013","journal-title":"Cell Stem Cell"},{"key":"2023122301070593200_bib62","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2013-03-492181","article-title":"Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies","volume":"122","author":"Oaks","year":"2013","journal-title":"Blood"},{"key":"2023122301070593200_bib63","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.cell.2010.01.007","article-title":"miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts","volume":"140","author":"Eiring","year":"2010","journal-title":"Cell"},{"key":"2023122301070593200_bib64","doi-asserted-by":"crossref","first-page":"23885","DOI":"10.1038\/srep23885","article-title":"Tracking of normal and malignant progenitor cell cycle transit in a defined niche","volume":"6","author":"Pineda","year":"2016","journal-title":"Sci Rep"},{"key":"2023122301070593200_bib65","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1172\/JCI66517","article-title":"BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression","volume":"123","author":"Roccaro","year":"2013","journal-title":"J Clin Invest"},{"key":"2023122301070593200_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/0471143030.cb0322s30","article-title":"Isolation and characterization of exosomes from cell culture supernatants and biological fluids","author":"Thery","year":"2006","journal-title":"Curr Protoc Cell Biol"},{"key":"2023122301070593200_bib67","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI31095","article-title":"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia","volume":"117","author":"Neviani","year":"2007","journal-title":"J Clin Invest"},{"key":"2023122301070593200_bib68","doi-asserted-by":"crossref","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"key":"2023122301070593200_bib69","doi-asserted-by":"crossref","first-page":"W159","DOI":"10.1093\/nar\/gkt379","article-title":"ComiR: combinatorial microRNA target prediction tool","volume":"41","author":"Coronnello","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"2023122301070593200_bib70","doi-asserted-by":"crossref","first-page":"D360","DOI":"10.1093\/nar\/gkx1144","article-title":"mirDIP 4.1-integrative database of human microRNA target predictions","volume":"46","author":"Tokar","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"2023122301070593200_bib71","doi-asserted-by":"crossref","first-page":"e0181231","DOI":"10.1371\/journal.pone.0181231","article-title":"CSmiRTar: condition-specific microRNA targets database","volume":"12","author":"Wu","year":"2017","journal-title":"PLoS One"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/1\/1\/48\/3392674\/48.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/1\/1\/48\/3392674\/48.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T20:07:42Z","timestamp":1703275662000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/1\/1\/48\/35112\/Persistence-of-Drug-Resistant-Leukemic-Stem-Cells"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":71,"aliases":["10.1158\/2643-3249.bcd-19-0039"],"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,3,4]]},"published-print":{"date-parts":[[2020,6,19]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.bcd-19-0039","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.22363946","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22363961.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22363949","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22363964","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22363955","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22363967","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22363955.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22363961","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22363973","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22363970","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22363970.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22363967.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22363964.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22363973.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22363946.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22363949.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.6493958.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.6493958","asserted-by":"object"},{"id-type":"doi","id":"10.1101\/680108","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,4]]}}}